Atrial fibrillation in a primary care practice: Prevalence and management

被引：12

作者：

Ceresne L. ^{[1
]}

Upshur R.E. ^{[1
,2
]}

机构：

[1] Dept. of Fam. and Community Medicine, University of Toronto, Toronto, Ont.

[2] Primary Care Research Unit, Dept. of Fam. and Community Medicine, University of Toronto, Toronto, Ont.

来源：

BMC Family Practice | / 3卷 / 1期

关键词：

Atrial Fibrillation; Warfarin; Ticlopidine; Paroxysmal Atrial Fibrillation; Warfarin Therapy;

D O I：

10.1186/1471-2296-3-11

中图分类号：

学科分类号：

摘要：

Background: Atrial fibrillation is a common serious cardiac arrhythmia. Knowing the prevalence of atrial fibrillation and documentation of medical management are important in the provision of primary care. This study sought to determine the prevalence of atrial fibrillation in a primary care population and to identify and quantify the treatments being used for stroke prevention in this group of patients. Methods: A prevalence study through chart audit was conducted in the family medicine practice at the Sunnybrook campus of the Sunnybrook and Women's College Health Sciences Centre. The main outcome measures were the prevalence of atrial fibrillation in our primary care practice and the use of warfarin for stroke prevention in this population. Results: 261 patients in our practice have atrial fibrillation. The overall prevalence in our family practice unit is 3.9%. When considering patients aged 60 and over, the prevalence rises to 12.2%. 204 of our patients with atrial fibrillation (78.2%) are currently being treated with warfarin. Another 21 patients were previously treated and discontinued for a number of reasons. Of the 57 patients not currently treated with warfarin, 44 are treated with ASA, 2 with ticlopidine, and 11 are receiving no preventative treatment. Conclusions: The prevalence of atrial fibrillation in our practice is higher than the range of prevalence reported in the general literature. However, our coverage with warfarin treatment exceeds previous reports in the literature.

引用

页码：1 / 6

页数：5

共 23 条

[1]

Bungard T.J., Ghali W.A., Teo K.K., McAlister F.A., Tsuyuki R.T., Why do patients with atrial fibrillation not receive warfarin?, Arch Intern Med, 160, pp. 41-46, (2000)

[2]

Antithrombotics and stroke in AF, Bandolier [Electronic], 70, 2, (1999)

[3]

Hart R.G., Benavente O., McBride R., Pearce L.A., Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis, Ann Intern Med, 131, pp. 492-501, (1999)

[4]

Benavente O., Hart R., Koudstaal P., Laupacis A., McBride R., Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks, The Cochrane Library, 3, (2001)

[5]

Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation, Can J Cardiol, 14, pp. 695-702, (1998)

[6]

Li-Saw-Hee F.L., Lip G.Y., Atrial fibrillation, thromboembolism and antithrombotic therapy, Int J Clin Pract, 53, pp. 110-117, (1999)

[7]

Smith N.L., Psaty B.M., Furberg C.D., White R., Lima J.A., Newman A.B., Manolio T.A., Temporal trends in the use of anticoagulants among older adults with atrial fibrillation, Arch Intern Med, 159, pp. 1574-1578, (1999)

[8]

Mead G.E., Wardlaw J.M., Lewis S.C., McDowall M., Dennis M.S., The influence of randomized trials on the use of anticoagulants for atrial fibrillation, Age Ageing, 28, pp. 441-446, (1999)

[9]

Hart R.G., Warfarin in atrial fibrillation: Underused in the elderly, often inappropriately used in the young, Heart, 82, pp. 539-540, (1999)

[10]

Perez I., Melbourn A., Kalra L., Use of antithrombotic measures for stroke prevention in atrial fibrillation, Heart, 82, pp. 570-574, (1999)

← 1 2 3 →